Germany is also a technology leader in cannabis research: Development of a solution for the vaporisation of medicinal cannabis extracts as a new application in cannabis therapy

The Tuttlingen-based company Storz & Bickel and the Berlin-based phytopharmaceutical manufacturer Becanex have entered into a strategic alliance to investigate the release of active ingredients from cannabinoids from the Becanex PIEX 70% THC crude extract product family on the MIGHTY + MEDIC and VOLCANO MEDIC 2 vaporisers from Storz & Bickel. Solutions for the safe and precisely dosable vaporisation of medicinal extracts are currently lacking for cannabis therapy.

The project will run for six months. In addition to analysing the release of active ingredients, the aim is to investigate the extent to which the vaporiser and extract may need to be adapted in order to enable the stable and easily dosed vaporisation of raw cannabis extracts. The results are an important milestone for a longer-term collaboration in joint product development.

The starting point for the co-operation is the complementary product portfolio. Storz & Bickel is a pioneer in the cannabis industry and offers the only certified vaporisers for medical use. Becanex produces high THC cannabis crude extracts, which contain a ratio of THC and terpenes corresponding to the flower and can be used in vaporisers at the same time. The combination of both products offers the first real alternative to the use of cannabis flower with rapid release of the active ingredient.

Storz & Bickel vaporisers are internationally recognised for their medical approval and outstanding product quality. Thanks to precise temperature control, they enable the gentle extraction of cannabinoids into an inhalable aerosol without releasing harmful combustion products. ‘We are pleased to take this important step to further facilitate patient access to effective and safe cannabis therapy,’ says Jürgen Bickel, Managing Director of Storz & Bickel.

The starting material for the production of the crude extract are dried flowers of Cannabis sativa L., which correspond to the Ph. Eur. - Monograph ‘Cannabis Flowers’ and are obtained from qualified suppliers. The specification of the THC crude extract is based on the DAB monograph ‘Adjusted Cannabis Extract’ and fulfils additional microbiological requirements for non-sterile inhaled dosage forms (Ph. Eur. Chapter 5.1.4). ‘After more than 10 years of research, our extraction technology enables the production of highly concentrated cannabis extracts with a flowable viscosity and flower-like terpene profile that are ideal for vaporisation. We are grateful to have found an experienced partner in Storz & Bickel to further develop the application in practice,’ says Managing Director Sebastian Kamphorst of Becanex GmbH.

We would be delighted if you included our press release in your reporting and would be happy to answer any questions and arrange interviews.

Contact for media enquiries: 
 

Storz & Bickel GmbH

Vatra Krasniqi (Head of Marketing and Communication)

Vatra.krasniqi@storz-bickel.com

About STORZ & BICKEL GmbH:

STORZ & BICKEL GmbH is the world's leading manufacturer of high-quality and medically certified cannabis inhalers. With its commitment to quality, innovation and compliance, the company has consistently delivered exceptional products that meet the highest industry standards. Based in Tuttlingen, Germany, STORZ & BICKEL is constantly driving the advancement of vaporisation technology, offering patients a safe and efficient way to consume cannabis for medicinal purposes. Storz & Bickel is part of Canopy Growth Corporation.

For more information, visit www.storz-bickel.com/ www.vapormed.com

Becanex GmbH

Sebastian Kamphorst (Managing Director)
sebastian@becanex.com

About Becanex

Becanex is currently the only producer of cannabis extracts in Germany. The company produces both raw cannabis extracts and discontinued cannabis extracts. Becanex has a manufacturing authorisation according to § 13 para. 1 AMG and the GMP certificate and is registered as an active ingredient manufacturer according to § 64 para. 3g AMG. The extracts are characterised by good viscosity and a high terpene content, the ‘flower in a bottle’. Becanex was founded in 2018 by Managing Director Sebastian Kamphorst and the current Technical Director Eral Osmanoglou and employs 15 people. Production takes place at the Berlin-Adlershof site. Becanex sells its products under its own name and produces cannabis extracts on a contract basis for European companies.